• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

AXA Framlington Biotech Fund Z Acc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider AXA Investment Managers UK Limited
Fund Summary The aim of this Fund is to provide long-term capital growth.
SEDOL code B784NS1
ISIN GB00B784NS11
Fund code FMBTA
Managers Linden Thomson, Dani Saurymper
Manager Tenure 7 years
Morningstar Category Sector Equity Biotechnology
IMA Sector Specialist
Fund Size £398 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 0.82%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £3.279
Buy Price £3.279
Price Change -0.213%
Price Date 20th September 2019
Yield Currently unavailable
Dividend Frequency Semi-Annually
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 27th November 2001
Fund Status OPEN

3-year Mean Monthly Return: 0.612%

Annual Returns 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Fund Performance +1.05% +7.85% +27.17% -21.98% +56.18% +33.86% +40.87% +22.02% +23.29% +0.92%
Benchmark Performance
(Sector Equity Biotechnology)
-0.50% +8.48% +28.16% -20.86% +48.04%
Time Period Cumulative Benchmark Performance
(Sector Equity Biotechnology)
Fund Compared to Benchmark
1 day -0.21% -0.48% +0.27%
1 week -0.21% -0.45% +0.23%
1 month -6.93% +0.44% -7.37%
3 months -7.35% -5.05% -2.30%
6 months -8.64% +0.12% -8.76%
1 year -9.17% -2.15% -7.01%
3 years 10.85% +31.77% -20.92%
5 years 44.07% +65.47% -21.40%
10 years 317.77% +372.96% -55.19%
YTD 10.18% +10.66% -0.48%
Since inception 286.13% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Gilead Sciences Inc USA 7.63%
Alexion Pharmaceuticals Inc USA 7.00%
Celgene Corp USA 6.63%
Biogen Inc USA 6.54%
Amgen Inc USA 4.98%
Illumina Inc USA 3.44%
Biomarin Pharmaceutical Inc USA 3.38%
Vertex Pharmaceuticals Inc USA 3.25%
Takeda Pharmaceutical Co Ltd JPN 2.95%
Incyte Corp USA 2.63%

Currently unavailable